Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT ® ...

Eisai Co., Ltd. announced today the company will present the latest findings from its Alzheimer's disease (AD) research, including lecanemab (brand name: LEQEMBI®), our anti-amyloid beta (A?) ...

On June 15, 2026, Circular Action Alliance (CAA) submitted its inaugural Program Plan to California’s Packaging Producer Responsibility ...

Top line data readout expected in late Q3/early Q4; INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase ...

Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the ...

Lipid-based nanocarriers, particularly liposomes, have played a central role in the development of modern drug delivery ...

Modern OCT devices can look inside the eye without a scalpel - but they do not always capture everything that matters. Some ...

Modern OCT devices can look inside the eye without a scalpel - but they do not always capture everything that matters. Some critical information is ...

MaxLinear's data center momentum, rising revenue outlook and surging EPS estimates help it edge past Qualcomm in this wireless chip stock matchup.

Detailed price information for Creative Medical Technology Holdings Inc (CELZ-Q) from The Globe and Mail including charting and trades.

Detailed price information for Akari Therapeutics ADR (AKTX-Q) from The Globe and Mail including charting and trades.